ID   Ov4Cis-Luc
AC   CVCL_E5FP
RX   PubMed=35918200;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Leu130Val (c.388C>G); ClinVar=VCV000458543; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transduction; Gene=FPbase; EGE3L; DsRed (Note=drFP583, red fluorescent protein from Discosoma sp.).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P08659; Firefly luciferase.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_E5FN ! OV4Cis
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=35918200; DOI=10.1016/j.ygyno.2022.07.027;
RA   Hoare J.I., Hockings H., Saxena J., Silva V.L., Haughey M.J., Wood G.E.,
RA   Nicolini F., Mirza H., McNeish I.A., Huang W.-N., Maniati E.,
RA   Graham T.A., Lockley M.;
RT   "A novel cell line panel reveals non-genetic mediators of platinum
RT   resistance and phenotypic diversity in high grade serous ovarian
RT   cancer.";
RL   Gynecol. Oncol. 167:96-106(2022).
//